Hikma Pharmaceuticals PLC (HIK.L)
23 Apr 2018
Mon, Mar 12 2018
GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug.
* HAS RECEIVED A RESPONSE FROM U.S. FDA IN RELATION TO ITS ANDA FOR ITS GENERIC VERSION OF GLAXOSMITHKLINE'S ADVAIR DISKUS
March 12 Hikma Pharmaceuticals Plc said on Monday it plans a new clinical study on its generic version of GlaxoSmithKline's popular lung drug Advair, as it looks to resolve an ongoing dispute with the Food and Drug Administration over plans to launch the drug in the U.S.
Feb 20 Hikma Pharmaceuticals Plc named former Teva Pharmaceutical executive Sigurdur Olafsson as its CEO, as the Jordan-based drugmaker looks to improve its struggling generics business.
* SAYS OLAFSSON WILL ALSO JOIN HIKMA'S BOARD OF DIRECTORS AS AN EXECUTIVE DIRECTOR
Feb 20 Drugmaker Hikma Pharmaceuticals Plc said on Tuesday it appointed Sigurdur Olafsson as its chief executive, effective immediately.
Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.
Dec 19 Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.
* REACHES LICENSING AGREEMENT WITH CELLTRION FOR THIRD BIOSIMILAR PRODUCT IN MIDDLE EAST AND NORTH AFRICA
* VENTURE CAPITAL ARM, HIKMA VENTURES HAS PARTICIPATED IN A $20.5 MILLION SERIES C ROUND OF FINANCING FOR PROGNOS Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)